Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Net Income towards Common Stockholders (2021 - 2025)

Prime Medicine filings provide 5 years of Net Income towards Common Stockholders readings, the most recent being -$46.1 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 9.0% to -$46.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$201.1 million, a 2.69% decrease, with the full-year FY2025 number at -$201.1 million, down 2.69% from a year prior.
  • Net Income towards Common Stockholders hit -$46.1 million in Q4 2025 for Prime Medicine, up from -$50.6 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$22.8 million in Q3 2021 to a low of -$69.3 million in Q4 2021.
  • Median Net Income towards Common Stockholders over the past 5 years was -$45.9 million (2024), compared with a mean of -$46.1 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: skyrocketed 41.4% in 2022 and later tumbled 61.69% in 2023.
  • Prime Medicine's Net Income towards Common Stockholders stood at -$69.3 million in 2021, then skyrocketed by 41.4% to -$40.6 million in 2022, then plummeted by 61.69% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then dropped by 9.0% to -$46.1 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$46.1 million (Q4 2025), -$50.6 million (Q3 2025), and -$52.6 million (Q2 2025) per Business Quant data.